NCT00344942

Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults

A Randomised, Double-blind, French Multi-centre Study, to Evaluate the Efficacy and Tolerance, in Comparison With Placebo, of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: Sanofi · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To demonstrate the superiority of the clinical efficacy of 12 weeks' treatment with Nasacort versus placebo in adult patients presenting with Chronic Non Allergic and Non Infectious Rhinitis

Conditions

• Rhinitis

Interventions

Type	Name	Description
DRUG	triamcinolone acetonide	220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
DRUG	placebo	a double spray into each nostril once daily

Timeline

• Start date: 2006-04-01
• Primary completion: 2007-04-01
• First posted: 2006-06-27
• Last updated: 2009-12-07

Locations

1 site across 1 country: France